Granulysin Antibody [PE]
Novus Biologicals, part of Bio-Techne | Catalog # AF3138P
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
Western Blot, Intracellular Staining by Flow Cytometry, CyTOF-ready
Label
PE (Excitation = 488 nm, Emission = 575 nm)
Antibody Source
Polyclonal Goat IgG
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Mouse myeloma cell line NS0-derived recombinant human Granulysin
Arg23-Leu145
Accession # P22749
Arg23-Leu145
Accession # P22749
Specificity
Detects human Granulysin in direct ELISAs and Western blots. In direct ELISAs and Western blots, less than 1% cross-reactivity with recombinant human NKG-2D is observed.
Clonality
Polyclonal
Host
Goat
Isotype
IgG
Applications for Granulysin Antibody [PE]
Application
Recommended Usage
CyTOF-ready
Optimal dilutions of this antibody should be experimentally determined.
Intracellular Staining by Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Western Blot
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Antigen Affinity-purified
Formulation
PBS
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: Granulysin
Alternate Names
GNLY, LAG2, Lymphokine, NKG5, TLA519
Gene Symbol
GNLY
Additional Granulysin Products
Product Documents for Granulysin Antibody [PE]
Product Specific Notices for Granulysin Antibody [PE]
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...